Navigation Links
AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting
Date:6/1/2009

QUEBEC CITY, June 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AEZS-108 (formerly AN-152), in prostate cancer. The presentation was made during yesterday's poster session at the American Society of Clinical Oncology (ASCO) Annual Meeting, being held through June 2, 2009 at the Orange County Convention Center in Orlando, Florida.

The poster (#5163) entitled, "Expression of LHRH receptors in prostate cancer cells prior to therapy, following castration, or following treatment with LHRH agonists," S. Liu, A. V. Schally, S. Xiong, R. Cote, D. Hawes, L. Fazli, M. Gleave, J. Cai, F. Brands, J. Engel, J. Pinski, investigates the expression of Luteinizing Hormone Releasing Hormone (LHRH) receptors following prolonged exposure to LHRH agonists.

"Results presented are important for the expansion of potential indications for our anti-cancer compound, AEZS-108", stated Juergen Engel, Ph.D., President and CEO of AEterna Zentaris. "While clinical investigations so far focused on gynaecological indications, the new results show continued expression of LHRH receptors in prostate cancer specimens after prolonged use of LHRH agonists; these data provide further support to the investigation of AEZS-108 in hormone-refractory prostate cancer, a major genitourinary cancer indication in male patients."

Results

LHRH receptor expression was demonstrated in more than 95% of 130 prostate cancer specimens analyzed, irrespective of origin (primary tumor, metastases) or patients' prior hormonal treatment (none, castration, LHRH agonist). In all groups, the majority of specimens showed moderate to strong receptor expression. Statistically, strong receptor expression correlated with higher pathologic tumor stage and shorter overall survival.

    Conclusion

    - In virtually all patients with prostate cancer, tumor cells appear to
      express LHRH receptors;
    - Even tumors persisting or relapsing after castration or prolonged
      hormonal treatment with LHRH agonists retain the expression of LHRH
      receptors;
    - The continued expression of these receptors supports the concept of
      targeting prostatic LHRH receptors to deliver cytotoxic therapy based
      on LHRH analogs, such as AEZS-108.

A copy of the abstract is currently available and can be viewed on-line through the ASCO website: http://www.asco.org/.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements, and we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested to do so by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AEterna Zentaris to Present Data Supporting Evaluation of AEZS-108 in Prostate Cancer at Upcoming ASCO Meeting
2. AEterna Zentaris to Announce First Quarter 2009 Financial and Operating Results and Hold Annual Shareholder Meeting on May 6, 2009
3. AEterna Zentaris Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement
4. AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver
5. AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting
6. AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting
7. AEterna Zentaris Reports Fourth Quarter and Full-Year 2008 Financial and Operating Results
8. AEterna Zentaris to Announce Fourth Quarter and Full-Year 2008 Financial and Operating Results on March 11, 2009
9. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris to Present at Upcoming RBC Capital Markets Healthcare Conference
11. AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/16/2016)... 2016   EyeLock LLC , a market leader ... of an IoT Center of Excellence in ... development of embedded iris biometric applications. EyeLock,s ... and security with unmatched biometric accuracy, making it the ... DNA. EyeLock,s platform uses video technology to deliver a ...
(Date:4/28/2016)... -- First quarter 2016:   , Revenues ... first quarter of 2015 The gross margin was 49% ... and the operating margin was 40% (-13) Earnings per ... from operations was SEK 249.9 M (21.2) , Outlook ... 7,000-8,500 M. The operating margin for 2016 is estimated ...
Breaking Biology News(10 mins):